Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 19/20 | 0.75 |
| ▸ | NOS3 | P29474 | 18/20 | 0.75 |
| ▸ | NOS2 | P35228 | 9/20 | 0.75 |
| ▸ | HTR1D | P28221 | 1/20 | 0.59 |
| ▸ | HTR1B | P28222 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4137759 | 0.99 | NOS1 (0.74) | NOS1NOS3NOS2HTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL1122136 | 0.85 | NOS1 (0.98) | NOS1NOS3NOS2HTR1DHTR1B | |
| SCHEMBL1122439 | 0.83 | NOS3 (0.84) | NOS1NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL3416449 | 0.82 | NOS3 (0.82) | NOS1NOS3NOS2 | |
| SCHEMBL1121986 | 0.81 | NOS3 (1.00) | NOS1NOS3NOS2HTR1DHTR1B | |
| SCHEMBL1122145 | 0.81 | NOS1 (1.00) | NOS1NOS3NOS2HTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL3381603 | 0.80 | NOS3 (0.98) | NOS1NOS3NOS2 | |
| SCHEMBL1122333 | 0.79 | NOS3 (1.00) | NOS1NOS3NOS2 | |
| SCHEMBL28791382 | 0.78 | NOS3 (0.71) | NOS1NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL27832499 | 0.78 | NOS3 (0.69) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101910157-B | Indole compounds and methods of treating visceral pain | NEURAXON INC | 2014-05-07 | — | — | CN | disclosed |
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| EP-2220075-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | Neuraxon, INC. (CA) | 2010-08-25 | — | — | EP | disclosed |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| WO-2009062319-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | TPH1, NOS1, IDO1 | NOS1 2/4885NOS3 5/4885NOS2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.